Mutant superoxide dismutase 1-catalyzed hydrogen therapy for amyotrophic lateral sclerosis achieved by intercepting oxidative stress–neuroinflammation crosstalk
- 3 July 2026
- journal article
- Published by Elsevier in Acta Biomaterialia
- Vol. 219, 663-678
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 43 references indexed in Scilit:
- Modulating NLRP3 Inflammasome Activity and Enhancing Cortical Synaptic Plasticity: Nanoparticulate Hydrogen’s Role in Relief of Post-traumatic Anxiety-like Behaviors in RatsMolecular Neurobiology, 2025
- GDF15-GFRAL signaling drives weight loss and lipid metabolism in mouse model of amyotrophic lateral sclerosisBrain, Behavior, and Immunity, 2024
- Hydrogen Attenuates Cognitive Impairment in Rat Models of Vascular Dementia by Inhibiting Oxidative Stress and NLRP3 Inflammasome ActivationAdvanced Healthcare Materials, 2024
- Current therapy in amyotrophic lateral sclerosis (ALS): A review on past and future therapeutic strategiesEuropean Journal of Medicinal Chemistry, 2024
- Dietary NMN supplementation enhances motor and NMJ function in ALSExperimental Neurology, 2024
- Fe-porphyrin: A redox-related biosensor of hydrogen moleculeNano Research, 2022
- Oxidized DNA fragments exit mitochondria via mPTP- and VDAC-dependent channels to activate NLRP3 inflammasome and interferon signalingImmunity, 2022
- The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteinsGlia, 2019
- Suppressing mutation-induced protein aggregation in mammalian cells by mutating residues significantly displaced upon the original mutationBiochemical Engineering Journal, 2014
- Edaravone in ALSExperimental Neurology, 2009